Business
Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens
SOUTH SAN FRANCISCO, Calif., January 06, 2026--Cartography Biosciences, Inc., a biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced a strategic collaboration with Pfizer to discover tumor-selective antigens. Under the multi-year agreement, Cartography will apply its proprietary ATLAS and SUMMIT discovery platforms to identify and validate tumor-selective antigens in an undisclosed indication. Pfizer may opt in on multiple antigens identif
About this update from Pfizer, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1667,"height":272,"url":"https://media.zenfs.com/en/business-wire.com/498d686a42a5caecb4887367ec26a81d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eIDwK.dJiKfRW6_dGkk1ew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/498d686a42a5caecb4887367ec26a81d","width":960,"height":157},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/3.qs_sdt3p6Txr0HViWBJQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zOTI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/498d686a42a5caecb4887367ec26a81d","width":1200,"height":196}},"lazy":false},{"type":"text","content":"– Collaboration leverages Cartography’s cutting-edge ATLAS and SUMMIT platforms to identify tumor-selective antigens; Pfizer to lead therapeutic development –","length":158,"tagName":"p","attribs":{}},{"type":"text","content":"– Cartography to receive upfront, near-term milestone payments, and option exercise payments of up to $65 million, as well as additional development, regulatory and commercial milestone payments that could total over $800 million if all options are exercised –","length":260,"tagName":"p","attribs":{}},{"type":"text","content":"– Cartography’s lead program, CBI-1214, to remain wholly owned and independently advanced –","length":91,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., January 06, 2026--(BUSINESS WIRE)--Cartography Biosciences, Inc., a biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced a strategic collaboration with Pfizer to discover tumor-selective antigens. Under the multi-year agreement, Cartography will apply its proprietary ATLAS and SUMMIT discovery platforms to identify and validate tumor-selective antigens in an undisclosed indication. Pfizer may opt in on multiple antigens identified and validated through this collaboration and will be responsible for all research, development and commercialization of programs directed to selected antigens. Cartography’s lead program, CBI-1214, remains wholly owned and independently advanced by the company.","length":782,"tagName":"p"},{"type":"text","content":"A core component of the collaboration is the target analysis and identifi...